Considerations on the evolving landscape and ongoing unmet needs for patients with HER2+ breast cancer.
Thomas Bachelot, MD, PhD, Centre Leon Berard
Advertisement
Articles by Thomas Bachelot, MD, PhD, Centre Leon Berard
Volkmar Mueller, MD, shares insight on the potential sequencing of available therapeutics for patients with metastatic HER2+ breast cancer.
Experts discuss the clinical implications of the approval of tucatinib in Europe, specifically for patients with active brain metastases.
An examination of the real-world data supporting the use of tucatinib for patients with metastatic HER2+ breast cancer in Europe.
Experts in breast oncology review the favorable safety profile of tucatinib for patients with metastatic HER2+ breast cancer.
Volkmar Mueller, MD, reviews recent data from the HER2CLIMB trial and discusses the recent regulatory approval in Europe for patients with HER2+ breast cancer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
2
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
3
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
4
Anti–Gremlin-1 Therapy Plus Chemo Makes Waves in GI Malignancies
5